- Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia
-
Emmaline Zantua Fernando, Jeryl Ritzi Tan Yu, Salvador Miclat Abad Santos, Roland Dominic Go Jamora
-
J Mov Disord. 2021;14(1):75-77. Published online December 7, 2020
-
DOI: https://doi.org/10.14802/jmd.20091
-
-
6,205
View
-
124
Download
-
4
Web of Science
-
2
Crossref
-
 Abstract
 PDF Supplementary Material
- Hydroxychloroquine (HCQ) has been used as an investigational drug for patients with moderate to severe coronavirus disease 2019 (COVID-19). There have been concerns of potential harms from side effects of the drug. We present a case of a 38-year-old male who was started on HCQ for COVID-19 pneumonia. He was referred for evaluation of myoclonus of all extremities, which resolved after discontinuation of HCQ. The involuntary movements were first reported after the initiation of HCQ, persisted despite improvement in inflammatory and radiologic parameters and eventually resolved after HCQ discontinuation. This supports a possible causality related to adverse drug reactions from HCQ that have not been commonly reported.
-
Citations
Citations to this article as recorded by  - Safety profile of COVID-19 drugs in a real clinical setting
Mei Nee Chiu, Maitry Bhardwaj, Sangeeta Pilkhwal Sah
European Journal of Clinical Pharmacology.2022; 78(5): 733. CrossRef - Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revisão de escopo
Vinícius de Mello, Vinícius de Paula Pereira, João Paulo Vilela Rodrigues, Suelem Tavares da Silva Penteado, Leonardo Régis Leira Pereira, Fabiana Rossi Varallo
Revista Panamericana de Salud Pública.2022; 46: 1. CrossRef
|
KMDS
E-submission
